Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices

Left ventricular assist device (LVAD) is well established as an alternative treatment for end-stage heart failure (HF) patients. The aim of the study was to determine the prognostic value of oxidative stress markers and the modified Model for End-Stage Liver Disease (modMELD) in patients receiving b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bożena Szyguła-Jurkiewicz, Wioletta Szczurek-Wasilewicz, Mariusz Gąsior, Izabela Copik, Justyna Małyszek-Tumidajewicz, Michał Skrzypek, Ewa Romuk, Michał Zembala, Marian Zembala, Piotr Przybyłowski
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	oxidative stress modified model for end-stage liver disease heart failure left ventricular assist device Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/c0ec5e23b6e24fd4848105f0108a8880
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c0ec5e23b6e24fd4848105f0108a8880
record_format	dspace
spelling	oai:doaj.org-article:c0ec5e23b6e24fd4848105f0108a88802021-11-25T16:28:57ZOxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices10.3390/antiox101118132076-3921https://doaj.org/article/c0ec5e23b6e24fd4848105f0108a88802021-11-01T00:00:00Zhttps://www.mdpi.com/2076-3921/10/11/1813https://doaj.org/toc/2076-3921Left ventricular assist device (LVAD) is well established as an alternative treatment for end-stage heart failure (HF) patients. The aim of the study was to determine the prognostic value of oxidative stress markers and the modified Model for End-Stage Liver Disease (modMELD) in patients receiving bridged therapy with continuous-flow LVAD. We prospectively analyzed 36 end-stage HF patients who received LVAD therapy between 2015 and 2018. The total antioxidant capacity (TAC) and total oxidant status (TOS) were measured by the methods described by Erel. The oxidative stress index (OSI) was defined as the ratio of the TOS to TAC levels. The modMELD scores were calculated based on the serum bilirubin, creatinine, and albumin levels. The patients’ median age was 58 (50–63.0) years. During the 1.5-years follow-up, a major adverse cardiac event—MACE (death, stroke, or pump thrombosis) was observed in 17 patients (47.2%). The area under the receiver operating characteristics curves (AUCs) indicated a good prognostic power of TAC (AUC 0.7183 (0.5417–0.8948)), TOS (AUC 0.9149 (0.8205–0.9298)), OSI (AUC 0.9628 (0.9030–0.9821)), and modMELD (AUC 0.87 (0.7494–0.9905)) to predict a MACE. Oxidative stress markers serum concentrations, as well as the modMELD score, allow the identification of patients with a risk of MACE.Bożena Szyguła-JurkiewiczWioletta Szczurek-WasilewiczMariusz GąsiorIzabela CopikJustyna Małyszek-TumidajewiczMichał SkrzypekEwa RomukMichał ZembalaMarian ZembalaPiotr PrzybyłowskiMDPI AGarticleoxidative stressmodified model for end-stage liver diseaseheart failureleft ventricular assist deviceTherapeutics. PharmacologyRM1-950ENAntioxidants, Vol 10, Iss 1813, p 1813 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	oxidative stress modified model for end-stage liver disease heart failure left ventricular assist device Therapeutics. Pharmacology RM1-950
spellingShingle	oxidative stress modified model for end-stage liver disease heart failure left ventricular assist device Therapeutics. Pharmacology RM1-950 Bożena Szyguła-Jurkiewicz Wioletta Szczurek-Wasilewicz Mariusz Gąsior Izabela Copik Justyna Małyszek-Tumidajewicz Michał Skrzypek Ewa Romuk Michał Zembala Marian Zembala Piotr Przybyłowski Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices
description	Left ventricular assist device (LVAD) is well established as an alternative treatment for end-stage heart failure (HF) patients. The aim of the study was to determine the prognostic value of oxidative stress markers and the modified Model for End-Stage Liver Disease (modMELD) in patients receiving bridged therapy with continuous-flow LVAD. We prospectively analyzed 36 end-stage HF patients who received LVAD therapy between 2015 and 2018. The total antioxidant capacity (TAC) and total oxidant status (TOS) were measured by the methods described by Erel. The oxidative stress index (OSI) was defined as the ratio of the TOS to TAC levels. The modMELD scores were calculated based on the serum bilirubin, creatinine, and albumin levels. The patients’ median age was 58 (50–63.0) years. During the 1.5-years follow-up, a major adverse cardiac event—MACE (death, stroke, or pump thrombosis) was observed in 17 patients (47.2%). The area under the receiver operating characteristics curves (AUCs) indicated a good prognostic power of TAC (AUC 0.7183 (0.5417–0.8948)), TOS (AUC 0.9149 (0.8205–0.9298)), OSI (AUC 0.9628 (0.9030–0.9821)), and modMELD (AUC 0.87 (0.7494–0.9905)) to predict a MACE. Oxidative stress markers serum concentrations, as well as the modMELD score, allow the identification of patients with a risk of MACE.
format	article
author	Bożena Szyguła-Jurkiewicz Wioletta Szczurek-Wasilewicz Mariusz Gąsior Izabela Copik Justyna Małyszek-Tumidajewicz Michał Skrzypek Ewa Romuk Michał Zembala Marian Zembala Piotr Przybyłowski
author_facet	Bożena Szyguła-Jurkiewicz Wioletta Szczurek-Wasilewicz Mariusz Gąsior Izabela Copik Justyna Małyszek-Tumidajewicz Michał Skrzypek Ewa Romuk Michał Zembala Marian Zembala Piotr Przybyłowski
author_sort	Bożena Szyguła-Jurkiewicz
title	Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices
title_short	Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices
title_full	Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices
title_fullStr	Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices
title_full_unstemmed	Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices
title_sort	oxidative stress markers and modified model for end-stage liver disease are associated with outcomes in patients with advanced heart failure receiving bridged therapy with continuous-flow left ventricular assist devices
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c0ec5e23b6e24fd4848105f0108a8880
work_keys_str_mv	AT bozenaszygułajurkiewicz oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT wiolettaszczurekwasilewicz oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT mariuszgasior oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT izabelacopik oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT justynamałyszektumidajewicz oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT michałskrzypek oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT ewaromuk oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT michałzembala oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT marianzembala oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices AT piotrprzybyłowski oxidativestressmarkersandmodifiedmodelforendstageliverdiseaseareassociatedwithoutcomesinpatientswithadvancedheartfailurereceivingbridgedtherapywithcontinuousflowleftventricularassistdevices
_version_	1718413164361547776

Oxidative Stress Markers and Modified Model for End-Stage Liver Disease Are Associated with Outcomes in Patients with Advanced Heart Failure Receiving Bridged Therapy with Continuous-Flow Left Ventricular Assist Devices

Ejemplares similares